Bristol Myers Squibb (BMY) News Today

Bristol Myers Squibb Company (NYSE: BMY) shares have moved on a mix of clinical trial updates, analyst estimate revisions, insider activity, and new program launches. Investors are assessing potential breakthroughs in cardiovascular and psychiatric treatments, offset by missed trial endpoints and lowered earnings forecasts.

• Positive Sentiment: Milvexian Phase II cardiovascular study data suggests a potential game-changer in thrombosis treatment, boosting long-term growth prospects. Milvexian Study
• Positive Sentiment: Initiation of a new Alzheimer’s study indicates potential expansion into neurodegenerative treatments, diversifying BMY’s pipeline. Alzheimer’s Study
• Positive Sentiment: Positive interim results from the KarXT schizophrenia study hint at a promising new psychiatric drug candidate. KarXT Schizophrenia Study
• Positive Sentiment: BMY’s KarXT Phase II study in bipolar I disorder shows encouraging results, reinforcing expansion in psychiatric indications. KarXT Bipolar I Study
• Neutral Sentiment: BMY has become a trending stock on Zacks.com, reflecting elevated investor interest but unspecified impact on fundamentals. Trending Stock
• Neutral Sentiment: BMY and Pfizer launched a program to sell Eliquis directly to patients at a roughly 40% discount, which may expand access but pressure margins. Eliquis Direct-to-Patient
• Negative Sentiment: Reblozyl failed to meet the primary endpoint in a late-stage anemia trial for myelofibrosis patients, raising pipeline concerns. Reblozyl Trial Failure
• Negative Sentiment: William Blair lowered its Q2 EPS forecast to $1.03 (from $1.52) and cut FY2025 to $6.22, signaling potential near-term earnings pressure. William Blair Earnings Revision
• Negative Sentiment: Termination of BMY’s psoriasis study removes a potential new indication from the pipeline, tempering growth prospects. Psoriasis Study Termination
• Negative Sentiment: Rep. Virginia Foxx disclosed the sale of $1,001 to $15,000 of BMY shares, which may be viewed as a bearish insider signal. Insider Sale